Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy
In this study, at eight weeks after resumption of LEN after initial TACE, "deep response" was defined as achieving CR or PR on mRECIST, and at least a 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters as the reference. Results: The OS and PFS in the LEN-TACE group were significantly higher than those in the LEN monotherapy group (P = 0.002 and P = 0.037, respectively). The incidence of AEs related to LEN was not significantly different between the two groups. In LEN-TACE sequential therapy, the objective response rate was 61.9%, and the disease control rate was 74.6%, according to t...
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
Conclusion: Based on a favorable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200 mg BID. Studies to evaluate the antitumor activity of GNS561 in hepatocarcinoma cells and intrahepatic cholangiocarcinoma are to follow NCT 03316222. (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers
Conclusion - Based on a favourable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200mg BID. Studies to evaluate the antitumor activity of GNS561 in HCC and iCCA are to follow. NCT 03316222 (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conclusions In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034 (Source: Liver Cancer)
Source: Liver Cancer - February 10, 2022 Category: Cancer & Oncology Source Type: research

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review
Background: Multikinase inhibitors (MKIs) have been shown to improve survival in patients with hepatocellular carcinoma (HCC) compared with placebo. Distinct from other MKIs, cabozantinib has inhibitory activity for both AXL and MET. This review considers the literature elucidating the role of AXL and MET in HCC progression, treatment resistance, and immunomodulation. A systematic search of the PubMed database was conducted on November 16, 2020, and identified a total of 174 search results. A further 36 potentially relevant articles were identified based on the authors ’ knowledge. After initial screening by title/abstra...
Source: Liver Cancer - February 10, 2022 Category: Cancer & Oncology Source Type: research

Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience
Conclusions: These real-world data show that MWA provided an upward trend in survival for HCC patients with BCLC stage 0 –B over a 12-year follow-up period. An encouraging clear survival benefit in early recurrent patients was also observed. (Source: Liver Cancer)
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: 12-year real-world multicentric experience
Introduction: Although being a promising technique for hepatocellular carcinoma (HCC) treatment, the 10-year efficacies of microwave ablation (MWA) are unknown. Objective: To assess whether the advances of MWA for HCC translated into a real-world survival benefit. Methods: This retrospective study included 2,354 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B from 5 hospitals, with at least 2 years of follow-up for all the patients. Recurrence and survival were analyzed using the Kaplan-Meier method with time-period stratification. Results: A total of 5,326 HCCs (mean diameter, 2.9 cm ± 1.2) underwent 4...
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

A hybrid machine learning model based on semantic information can optimize treatment decision for na ïve single 3-5cm HCC patients
Abstract: Background: Tumor recurrence is an abomination for hepatocellular carcinoma (HCC) patients receiving local treatment. Purpose: To build a hybrid machine learning model to recommend optimized first treatment (Laparoscopic hepatectomy (LH) or Microwave ablation (MWA)) for na ïve single 3-5cm HCC patients based on early recurrence (ER, ≤2 years) probability. Methods: This retrospective study collected 20 semantic variables of 582 patients (LH:300, MWA:282) from 13 hospitals with at least 24 months follow-up. Both groups were divided into training, validation and test set, respectively. Five algorithms (Logistic...
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma
Conclusion Genetic variant of CXCR1 +860 C>G may serve as a molecular marker for DFS, CSS and OS in patients undergoing curative-intent surgery for pCCA, indicating that the analysis of SNPs in genes involved in immune-mediated angiogenesis may help to identify patient subgroups at high risk for dismal oncological and overall outcome. (Source: Liver Cancer)
Source: Liver Cancer - January 25, 2022 Category: Cancer & Oncology Source Type: research

Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy
Conclusion: Baseline sPD-L1, sPD-L1 fold change, and cfDNA fold change values showed the highest potential as biomarkers for predicting post-treatment progression after LDCRT in HCC patients. By incorporating clinical factors, these biomarkers may be useful for devising a biomarker-driven treatment paradigm in locally advanced HCC. (Source: Liver Cancer)
Source: Liver Cancer - January 24, 2022 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2022;11:85 –85 (Source: Liver Cancer)
Source: Liver Cancer - January 20, 2022 Category: Cancer & Oncology Source Type: research

Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A retrospective multicenter study
Conclusion Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not revea l new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC. (Source: Liver Cancer)
Source: Liver Cancer - January 14, 2022 Category: Cancer & Oncology Source Type: research

Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small molecular weight tyrosine kinase-inhibitor (SMW TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors (ICIs) for advanced HCC, the management of patients has been greatly improved. Howeve...
Source: Liver Cancer - January 4, 2022 Category: Cancer & Oncology Source Type: research

Surgery Versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: a Randomized Controlled Trial (SURF-Trial)
Introduction: It remains unclear which of surgery or radiofrequency ablation (RFA) is the more effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival between patients undergoing surgery (surgery group) and patients undergoing RFA (RFA group). Methods: We conducted a randomized controlled trial involving 49 institutions in Japan. Patients with Child-Pugh scores ≤ 7, largest HCC diameter ≤ 3 cm, and ≤ 3 HCC nodules were considered eligible. The co-primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The current study reports the final result of RFS, and t...
Source: Liver Cancer - December 29, 2021 Category: Cancer & Oncology Source Type: research

LIM homeobox-2 suppresses hallmarks of adult and pediatric liver cancers by inactivating MAPK/ERK and Wnt/beta-catenin pathways
Conclusion: Collectively, our findings demonstrate a tumor suppressive function of LHX2 in adult and pediatric liver cancers. (Source: Liver Cancer)
Source: Liver Cancer - December 21, 2021 Category: Cancer & Oncology Source Type: research